# FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

> **NCT04832776** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 160 (estimated)

## Conditions studied

- Liver Metastasis Colon Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Bevacizumab
- **DRUG:** FOLFOXIRI

## Key facts

- **NCT ID:** NCT04832776
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-17
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2021-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04832776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04832776, "FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04832776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*